Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
| Autor: | Joanna Bougie, Holly Ge, Anders Ettrup, Guerline Clerzius, Pratap Chokka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
cognitive bias
Treatment outcome RC435-571 RM1-950 vortioxetine medicine In patient Pharmacology Toxicology and Pharmaceutics (miscellaneous) Original Research Psychiatry Vortioxetine Work productivity Cognitive Symptoms major depressive disorder business.industry anxiety work productivity medicine.disease Cognitive bias Major depressive disorder Anxiety Therapeutics. Pharmacology cognitive symptoms Psychology (miscellaneous) medicine.symptom business Clinical psychology |
| Zdroj: | Therapeutic Advances in Psychopharmacology Therapeutic Advances in Psychopharmacology, Vol 11 (2021) |
| ISSN: | 2045-1261 2045-1253 |
| DOI: | 10.1177/20451253211013148 |
| Popis: | Background: Anxiety symptoms are common in patients with major depressive disorder (MDD) and usually confer worse treatment outcomes. The long-term, open-label AtWoRC study in working patients with MDD treated with vortioxetine demonstrated a significant correlation between severity of anxiety symptoms and impaired work productivity. This analysis was undertaken to further explore clinical characteristics and treatment outcomes in patients with different levels of severity of anxiety symptoms at baseline. Methods: Post hoc analysis in 199 working patients with MDD treated with vortioxetine (10–20 mg/day), stratified by Generalized Anxiety Disorder 7-item (GAD-7) score at baseline [mild/moderate anxiety (GAD-7 ⩽14), n = 83; severe anxiety (GAD-7 ⩾15), n = 116]. Associations were examined between GAD-7 and other outcome assessment scores at baseline. Observed mean changes from baseline to week 52 were compared between groups. Results: Patients with severe anxiety had significantly worse depressive and cognitive symptoms, functioning, and work productivity at baseline than those with mild/moderate anxiety, but similar cognitive performance. Statistically significant improvements from baseline were seen for all outcomes after 52 weeks of vortioxetine treatment, with no significant differences observed between the two groups after adjustment for baseline anxiety scores. Conclusion: Treatment with vortioxetine was associated with long-term improvement in clinical symptoms and measures of work productivity in patients with MDD in a real-world setting, irrespective of severity of anxiety symptoms at the start of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|